DISCLOSURES
Shinichi
Akimichi Morita declares receiving research grants, consulting fees, and/or speaker's fees from AbbVie, Boehringer Ingelheim, Eisai, Eli Lilly, Janssen, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe, Nichi‐Iko, Nippon Kayaku, Novartis, Sun Pharmaceutical Industries, Taiho Pharmaceutical, Torii Pharmaceutical, and Ushio. Tsen‐Fang Tsai declares conducting clinical trials or paid consulting activities for AbbVie, Boehringer Ingelheim, Celgene, Eli Lilly, GSK, Janssen, MSD, Novartis, Pfizer, and UCB. Evelyn Yap Wen Yee declares being an investigator for AbbVie, AnaptysBio, Boehringer Ingelheim, La Roche‐Posay, and Novartis, and a consultant for AnaptysBio. Yukari Okubo declares receiving grants or contracts from Eisai, Maruho, and Torii Pharmaceutical, and consulting fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eisai, Eli Lilly, Janssen, JIMRO, Kyowa Kirin, LEO Pharma, Maruho, Novartis, Pfizer, Sanofi, Sun Pharmaceutical Industries, Taiho Pharmaceutical, Mitsubishi Tanabe, Torii Pharmaceutical, and UCB. Shinichi Imafuku has served as a consultant and/or paid speaker for and/or accepted a research grant from and/or participated in clinical trials sponsored by companies including AbbVie, Amgen, Eisai, Eli Lilly, Janssen, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe, Novartis, Sun Pharmaceutical Industries, Taiho Pharmaceutical, Torii Pharmaceutical, and UCB. Min Zheng declares receiving grants, consulting fees, and/or speaker's fees from AbbVie, Boehringer Ingelheim, Janssen, LEO Pharma China, Novartis, Pfizer, and Xian‐Janssen. Ling Li, Manuel Quaresma, and Christian Thoma are employees of Boehringer Ingelheim. Siew Eng Choon declares paid activities as an advisor, speaker, or consultant for AbbVie, Boehringer Ingelheim, Eli Lilly, Janssen, LEO Pharma, MSD, Novartis, Pfizer, Sanofi, and UCB. The authors met criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors did not receive payment related to the development of this manuscript. Boehringer Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy as well as intellectual property considerations.